UK grants rare disease patients early access to Akcea candidate

21 March 2018
vials_dugs_biologic_report_test_big

The UK business of Akcea Therapeutics (Nasdaq: AKCA) has received a positive scientific opinion for volanesorsen, from the country’s Early Access to Medicines Scheme (EAMS).

The judgment from the UK’s medicines regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), means eligible patients will be able to access volanesorsen before the European Medicines Agency formally rules on its regulatory status in Europe.

Akcea is developing volanesorsen for the treatment of familial chylomicronemia syndrome (FCS), a rare genetic lipid disorder.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical